Search results for "Rectal Cancer"

showing 10 items of 978 documents

TGF-β Dependent T-Cell Regulation in Colitis and Colon Cancer

2008

Transforming growth factor-β (TGF-β) is a potent growth inhibitor endowed with tumor-suppressing activity. Unfortunately, cancers are often resistant to such growth inhibition. This evasion frequently results from a genetic loss of functional TGF-β signaling components. On the other hand, cancer cells often produce high amounts TGF-β1 by themselves and sometimes respond to it with invasion and metastasis. Much effort is being done to develop therapeutic approaches to modulate TGF-β signaling in cancer cells either to inhibit the TGF-β-induced invasive phenotype or to reestablish its growth-inhibitory activities. However, TGF-β is a pleiotropic cytokine with important functions not only in c…

Colorectal cancermedicine.medical_treatmentT cellFOXP3Biologymedicine.diseaseMetastasisCytokinemedicine.anatomical_structureCancer cellmedicineCancer researchIL-2 receptorTransforming growth factor
researchProduct

Characteristics of the colorectal cancers diagnosed in the early 2000s in Italy. Figures from the IMPATTO study on colorectal cancer screening

2015

The impact of organized screening programmes on colorectal cancer (CRC) can be observed at a population level only several years after the implementation of screening. We compared CRC characteristics by diagnostic modality (screen-detected, non-screen-detected) as an early outcome to monitor screening programme effectiveness. Data on CRCs diagnosed in Italy from 2000 to 2008 were collected by several cancer registries. Linkage with screening datasets made it possible to divide the cases by geographic area, implementation of screening, and modality of diagnosis (screen-detected, non-screen-detected).We compared the main characteristics of the different subgroups of CRCs through multivariate …

Colorectal cancer; Colorectal cancer screening; Italy; Epidemiology; Public Health Environmental and Occupational HealthItalyEpidemiologyPublic Health Environmental and Occupational HealthSettore MED/42 - Igiene Generale E ApplicataColorectal cancerColorectal cancer screening
researchProduct

Incidence trends of colorectal cancer in the early 2000s in Italy. Figures from the IMPATTO study on colorectal cancer screening

2015

We utilised the IMPATTO study's archives to describe the 2000-2008 colorectal cancer (CRC) incidence rate trends in Italy, once screening programmes based on the faecal immunochemical test were implemented in different areas. Data on CRCs diagnosed in Italy from 2000 to 2008 in subjects aged 40-79 years were collected by 23 cancer registries. Incidence rate trends were evaluated as a whole and by macro-area (North-Centre and South-Islands), presence of a screening programme, sex, ten-year age class, anatomic site, stage at diagnosis, and pattern of diagnosis (screen-detected, non-screen-detected). The annual percent change (APC) of incidence rate trends, with 95% confidence intervals (95%CI…

Colorectal cancer; Fecal immunochemical test; Incidence rates; Italy; Screening; Epidemiology; Public Health Environmental and Occupational HealthItalyFecal immunochemical testEpidemiologyEnvironmental and Occupational HealthScreeningPublic Health Environmental and Occupational HealthSocio-culturaleIncidence ratesPublic HealthIncidence rateSettore MED/42 - Igiene Generale E ApplicataColorectal cancer
researchProduct

A Predictive System to Classify Preoperative Grading of Rectal Cancer Using Radiomics Features

2022

Although preoperative biopsy of rectal cancer (RC) is an essential step for confirmation of diagnosis, it currently fails to provide prognostic information to the clinician beyond a rough estimation of tumour grade. In this study we used a risk classification to stratified patient in low-risk and high-risk patients in relation to the disease free survival and the overall survival using histopathological post-operative features. The purpose of this study was to evaluate if low-risk and high-risk RC can be distinguished using a CT-based radiomics model. We retrospectively reviewed the preoperative abdominal contrast-enhanced CT of 40 patients with RC. CT portal-venous phase was used for manua…

Computed tomography Radiomics Rectal cancer Texture analysis
researchProduct

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

2012

Contains fulltext : 111010pub.pdf (Publisher’s version ) (Closed access) Colorectal cancer (CRC) is the most common tumour type in both sexes combined in Western countries. Although screening programmes including the implementation of faecal occult blood test and colonoscopy might be able to reduce mortality by removing precursor lesions and by making diagnosis at an earlier stage, the burden of disease and mortality is still high. Improvement of diagnostic and treatment options increased staging accuracy, functional outcome for early stages as well as survival. Although high quality surgery is still the mainstay of curative treatment, the management of CRC must be a multi-modal approach pe…

Counselingmedicine.medical_specialtyColorectal cancerDecision MakingColonoscopyDiseaseQuality of life (healthcare)Translational research [ONCOL 3]medicineHumansStage (cooking)Precision MedicineIntensive care medicinePatient Care Teammedicine.diagnostic_testbusiness.industryHematologyGuidelinePrecision medicinemedicine.diseasePrognosisSurgeryOncologyPersonalized medicinebusinessColorectal Neoplasms
researchProduct

P008 Differences in macrophage infiltration and Wnt ligands expression between stricturing and penetrating behaviour in Crohn’s disease

2018

Crohn's diseaseFrizzledbiologybusiness.industryColorectal cancermedicine.medical_treatmentGastroenterologyWnt signaling pathwayInterleukinGeneral Medicinemedicine.diseaseCytokineFibrosisCancer researchbiology.proteinMedicinebusinessInterleukin 6Journal of Crohn's and Colitis
researchProduct

The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models

2014

AbstractIn spite of the novel strategies to treat colon cancer, mortality rates associated with this disease remain consistently high. Tumour recurrence has been linked to the induction of resistance towards chemotherapy that involves cellular events that enable cancer cells to escape cell death. Treatment of colon cancer mainly implicates direct or indirect DNA-damaging agents and increased repair or tolerances towards subsequent lesions contribute to generate resistant populations. Resveratrol (RSV), a potent chemosensitising polyphenol, might share common properties with chemotherapeutic drugs through its indirect DNA-damaging effects reported in vitro. In this study, we investigated how…

Cyclin-Dependent Kinase Inhibitor p21SenescenceCancer ResearchProgrammed cell deathColonDNA damageColorectal cancerImmunologyApoptosisBiologyResveratrolS PhaseHistonesPolyploidyCellular and Molecular Neurosciencechemistry.chemical_compoundCell Line TumorStilbenesmedicineAnimalsHumansCHEK1Cyclin-Dependent Kinase Inhibitor p16Cell Biologymedicine.diseaseAntineoplastic Agents PhytogenicRatsGene Expression Regulation NeoplasticCheckpoint Kinase 2chemistryDrug Resistance NeoplasmResveratrolApoptosisCheckpoint Kinase 1Cancer cellImmunologyCancer researchOriginal ArticleTumor Suppressor Protein p53Reactive Oxygen SpeciesProtein KinasesDNA DamageSignal TransductionCell Death & Disease
researchProduct

Chemotherapy Sensitizes Colon Cancer Initiating Cells to Vγ9Vδ2 T Cell-Mediated Cytotoxicity

2013

Colon cancer comprises a small population of cancer initiating stem cells (CIC) that is responsible for tumor maintenance and resistance to anti-cancer therapies, possibly allowing for tumor recapitulation once treatment stops. Combinations of immune-based therapies with chemotherapy and other anti-tumor agents may be of significant clinical benefit in the treatment of colon cancer. However, cellular immune-based therapies have not been experimented yet in the population of colon CICs. Here, we demonstrate that treatment with low concentrations of commonly used chemotherapeutic agents, 5- fluorouracyl and doxorubicin, sensitize colon CICs to Vc9Vd2 T cell cytotoxicity. Vc9Vd2 T cell cytotox…

Cytotoxicity ImmunologicColorectal cancermedicine.medical_treatmentCancer TreatmentGene ExpressionPharmacologyTNF-Related Apoptosis-Inducing LigandCancer immunotherapyBasic Cancer ResearchImmune Responseeducation.field_of_studyMultidisciplinaryT CellsQColon AdenocarcinomaRReceptors Antigen T-Cell gamma-deltamedicine.anatomical_structureOncologyNK Cell Lectin-Like Receptor Subfamily KColonic NeoplasmsNeoplastic Stem CellsMedicineFluorouracilImmunotherapyResearch ArticleTumor ImmunologyImmune CellsScienceT cellPrimary Cell CultureImmunologyPopulationAntineoplastic AgentsAdenocarcinomaBiologyCell LineImmune systemGastrointestinal TumorsmedicineHumanseducationBiologyImmune EvasionImmunityCancers and NeoplasmsCancerImmunotherapyImmunologic Subspecialtiesmedicine.diseaseCoculture TechniquesReceptors TNF-Related Apoptosis-Inducing LigandDoxorubicinCancer researchClinical ImmunologyT cell mediated cytotoxicityT-Lymphocytes CytotoxicDR5 c9Vd2PLoS ONE
researchProduct

γδ T cells as a potential tool in colon cancer immunotherapy

2014

γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, the combined upregulation of T-cell receptorand NKG2D ligands on tumor cells and induction of NKG2D expression on γδ T cells may greatly enhance tumor killing and unlock the functions of γδ T cells. Here, we briefly review current data on the mechanisms of γδ T-cell recognition and killing of colon cancer cells and propose that γδ T cells may represent a promising target for the…

Cytotoxicity ImmunologicColorectal cancermedicine.medical_treatmentImmunologyNkg2d ligandsLarge rangeLigandsDownregulation and upregulationT-Lymphocyte SubsetsmedicineHumansImmunology and AllergyIn patientCell-mediated cytotoxicitybusiness.industryReceptors Antigen T-Cell gamma-deltaImmunotherapymedicine.diseaseNKG2Dgamma delta cellcolon cancerOncologyColonic NeoplasmsImmunologyNeoplastic Stem CellsImmunotherapybusinessImmunotherapy
researchProduct

Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials

2019

Abstract The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing datasets of primary tumor samples mainly from early stage colon cancer patients. Consequently, rectal tumors and stage IV tumors (possibly reflective of more aggressive disease) were underrepresented, and no chemo- and/or radiotherapy pretreated samples or metastatic lesions were included. In view of their possible effect on gene expression and consequently subtype classification, sample source and treatments received by the patients before collection must be ca…

Data Analysis0301 basic medicineOncologymedicine.medical_specialtyMicroarrayconsensus molecular subtypesColorectal cancermedicine.medical_treatmentDatasets as TopicReviews03 medical and health sciencesstratification0302 clinical medicineBiasCàncer colorectalInternal medicineBiomarkers TumormedicineHumansRNA-SeqOligonucleotide Array Sequence AnalysisClinical Trials as Topicclinical trialsbusiness.industryPatient SelectionBiochemical markersbiomarkersChemoradiotherapypersonalized medicineHematologyPrognosismedicine.diseaseChemotherapy regimenPrimary tumorColorectal cancerSubtypingRadiation therapyClinical trialTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationgene expressionPersonalized medicineNeoplasm Recurrence LocalColorectal NeoplasmsbusinessMarcadors biomquímics
researchProduct